Pulse Biosciences, Inc. filed a Form 8-K on September 15, 2026, announcing completion of patient enrollment in its PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules.
Key Highlights
- Enrollment complete: All 100 patients have been enrolled in the PRECISE-BTN clinical study, following an expansion from the original 50-patient design.
- First patient milestone: The first patient enrolled in the study completed their final 12-month follow-up visit.
- Three U.S. sites: Patients were enrolled across Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine.
- Enrollment timeline: All 100 patients were enrolled within approximately 12 months.
- Study endpoints: The protocol specifies follow-up visits at one, three, six, and twelve months post-procedure, with endpoints including safety, targeted nodule volume reduction, symptomatic relief, hormone normalization, and improvements in quality of life.
Pulse Biosciences Reports Full Enrollment and First 12-Month Follow-Up in PRECISE-BTN Study
According to the filing, Pulse Biosciences, Inc. (NASDAQ:PLSE) announced on September 15, 2026, that it has completed patient enrollment in the PRECISE-BTN clinical study. The study evaluates the company's nPulse Vybrance Percutaneous Electrode System as a treatment for symptomatic benign thyroid nodules. The company disclosed that enrollment was completed after the study was expanded from its original 50-patient design to 100 patients.
The filing states that all patients were enrolled across three U.S. clinical sites, identified as Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine, and that this enrollment occurred within approximately 12 months. The company also disclosed that the first patient enrolled in the study had completed their final 12-month follow-up visit, marking a procedural milestone in the study's progress.
As described in the filing, the PRECISE-BTN study protocol specifies follow-up visits at one, three, six, and twelve months post-procedure. The company indicated that study endpoints include safety, targeted nodule volume reduction, symptomatic relief, hormone normalization, and improvements in quality of life. The filing was signed by Jon Skinner, Chief Financial Officer, in his capacity as Principal Financial Officer.
What Was Disclosed
Pulse Biosciences disclosed completion of enrollment in its 100-patient PRECISE-BTN clinical study, the completion of the first patient's 12-month follow-up, the three participating U.S. clinical sites, and the study's specified endpoints and follow-up schedule.



Please wait processing your request...